Liu Jue, Xiang Tingkai, Wang Wei, Bu Zhangyu
Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
The Fourth School of Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Clin Cosmet Investig Dermatol. 2022 Jul 21;15:1391-1396. doi: 10.2147/CCID.S373682. eCollection 2022.
Bullous pemphigoid (BP) is an autoimmune blistering disease mainly affecting elderly individuals. Comorbidities are common in patients with BP and have been found to complicate the management and prognosis. We describe a patient with multiple comorbidities who was successfully treated with omalizumab and suggest omalizumab as a good alternative therapy for BP to prevent treatment-related complications in elderly patients with a poor general condition.
大疱性类天疱疮（BP）是一种主要影响老年人的自身免疫性水疱病。合并症在BP患者中很常见，并且已发现会使治疗和预后复杂化。我们描述了一名患有多种合并症的患者，该患者接受奥马珠单抗治疗成功，并建议将奥马珠单抗作为BP的一种良好替代疗法，以预防一般状况较差的老年患者发生与治疗相关的并发症。
